ACTG Presents Study at CROI Demonstrating Potential of CMV-specific Antiviral Inhibitor to Improve Aging-Related Outcomes among People Living with HIV and CMV (Cytomegalovirus) (GlobeNewswire) - Mar 12, 2025 - P2 | N=44 | ELICIT (NCT04840199) | "Today's presentation demonstrated that treatment with letermovir led to a significant increase in CD4 counts, with the most pronounced benefits seen in women and individuals whose CD4 T cells remained persistently low. Additionally, those receiving letermovir showed improvements in their CD4/CD8 ratio (a marker of immune system dysregulation that is associated with heart disease, cancer, and mortality in people living with HIV and in elderly populations) and physical function, including an enhancement in chair rise performance (a marker of leg strength and mobility). In addition, improvements in physical function with letermovir correlated strongly with the immunologic improvement observed, suggesting that these beneficial effects were closely linked."
P2 data • Cytomegalovirus Infection • Human Immunodeficiency Virus
|